Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Abstract A2-29: A PDK1 inhibitors that has antitumor activity in a vemurafenib resistant BRAF(V600E)::NRAS(G12V) melanoma PDX

Brian P. James, Robert Lemos, Jr., Stacey Bagby, Steven Robinson, William Robinson, John Tentler, S. Gail Eckhardt, D. Lynn Kirkpatrick, Garth Powis

Cancer Res (2015) 75 (22_Supplement_1): A2-29.

https://doi.org/10.1158/1538-7445.TRANSCAGEN-A2-29

Published: 15 November 2015

View article titled, Abstract A2-29: A PDK1 inhibitors that has antitumor activity in a vemurafenib resistant BRAF(V600E)::NRAS(G12V) melanoma PDX

Journal Articles

Abstract 2583: Refinement of inhibitors of the KRAS-signaling naocluster protein, CNKSR1, that block oncogenic KRAS signaling and growth

D. Lynn Kirkpatrick, Martin Indarte, Mike Scott, Assael Madrigal, Geoffrey Grandjean, Garth Powis

Cancer Res (2015) 75 (15_Supplement): 2583.

https://doi.org/10.1158/1538-7445.AM2015-2583

Published: 01 August 2015

View article titled, Abstract 2583: Refinement of inhibitors of the KRAS-signaling naocluster protein, CNKSR1, that block oncogenic KRAS signaling and growth

Journal Articles

Abstract 2671: Targeting the KRAS signaling naocluster protein CNKSR1 provides antitumor activity against mutant KRAS xenografts

Gallen Triana-Balzer, Martin Indarte, Mike Scott, Garth Powis, D. Lynn Kirkpatrick

Cancer Res (2014) 74 (19_Supplement): 2671.

https://doi.org/10.1158/1538-7445.AM2014-2671

Published: 01 October 2014

View article titled, Abstract 2671: Targeting the KRAS signaling naocluster protein CNKSR1 provides antitumor activity against mutant KRAS xenografts

Journal Articles

Abstract 5621: Single-walled carbon nanotubes for delivery of siRNA: Antitumor efficacy comparing formulated complexes in EGFR overexpressing A431 xenografts.

D. Lynn Kirkpatrick, Olga Gliko, Michelle Weiss, Iris Owusu, Anton Naumov

Cancer Res (2013) 73 (8_Supplement): 5621.

https://doi.org/10.1158/1538-7445.AM2013-5621

Published: 15 April 2013

View article titled, Abstract 5621: Single-walled carbon nanotubes for delivery of siRNA: Antitumor efficacy comparing formulated complexes in EGFR overexpressing A431 xenografts.

Journal Articles

Abstract 4481: Topical application of the dual PDPK1/AKT inhibitor PHT-427 inhibits signaling and growth of human breast cancer cutaneous metastases in mice

D. Lynn Kirkpatrick, Jenny L.H. Johnson, Robert Lemos, Mena Abdelemelek, Nathan Ihle, Garth Powis

Cancer Res (2011) 71 (8_Supplement): 4481.

https://doi.org/10.1158/1538-7445.AM2011-4481

Published: 15 April 2011

View article titled, Abstract 4481: Topical application of the dual PDPK1/AKT inhibitor PHT-427 inhibits signaling and growth of human breast cancer cutaneous metastases in mice

Journal Articles

Abstract 1975: PHuDock®, a computational discovery and development platform for novel PH domain-binding agents, identifies a novel antitumor AKT/PDPK1 inhibitor, PHT- 427

Shuxing Zhang, Emmanuelle Meuillet, Garth Powis, D. Lynn Kirkpatrick

Cancer Res (2010) 70 (8_Supplement): 1975.

https://doi.org/10.1158/1538-7445.AM10-1975

Published: 15 April 2010

View article titled, Abstract 1975: PHuDock®, a computational discovery and development platform for novel PH domain-binding agents, identifies a novel antitumor AKT/PDPK1 inhibitor, PHT- 427

Journal Articles

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Nathan T. Ihle, Robert Lemos, Jr., Peter Wipf, Adly Yacoub, Clint Mitchell, Doris Siwak, Gordon B. Mills, Paul Dent, D. Lynn Kirkpatrick, Garth Powis

Cancer Res (2009) 69 (1): 143–150.

https://doi.org/10.1158/0008-5472.CAN-07-6656

Published: 31 December 2008

View article titled, Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Journal Articles

Cellular and in vivo activity of a new PI3K inhibitor-PX866 for treatment of human glioblastoma.

Dimpy Koul, Ruijun Shen, Jennifer Edge, Verlene Henry, Douglas Webb, Jim Bankson, Sabrina Ronen, Garth Powis, D Lynn Kirkpatrick, Alfred WK Yung

Cancer Res (2008) 68 (9_Supplement): 3731.

Published: 01 May 2008

View article titled, Cellular and in vivo activity of a new PI3K inhibitor-PX866 for treatment of human glioblastoma.

Journal Articles

Molecular pharmacology and antitumor activity of palmarumycin based inhibitors of thioredoxin reductase

Garth Powis, Peter Wipf, Robert M. Halter, D. Lynn Kirkpatrick

Cancer Res (2006) 66 (8_Supplement): 1141.

Published: 15 April 2006

View article titled, Molecular pharmacology and antitumor activity of palmarumycin based inhibitors of thioredoxin reductase

Journal Articles

Clinical surrogate endpoint for the evaluation of HIF-1α inhibition by PX-478.

Linda A. Pestano, Jeffrey Millard, Garth Powis, D. Lynn Kirkpatrick

Cancer Res (2005) 65 (9_Supplement): 110.

Published: 01 May 2005

View article titled, Clinical surrogate endpoint for the evaluation of HIF-1α inhibition by PX-478.

Journal Articles

Pharmacodynamic proteomic studies of the thioredoxin-1 inhibitor PX-12 in mice and patients.

Amanda F. Baker, Tomislav Dragovich, Wendy R. Tate, D. Lynn Kirkpatrick, Garth Powis

Cancer Res (2004) 64 (7_Supplement): 845.

Published: 01 April 2004

View article titled, Pharmacodynamic proteomic studies of the thioredoxin-1 inhibitor PX-12 in mice and patients.

Journal Articles

Pharmacokinetic and pharmacodynamic studies of a novel antitumor wortmannin analogue inhibitor of phosphatidylinositol-3-kinase

Garth Powis, Nathan T. Ihle, Robert Abraham, D. Lynn Kirkpatrick, Peter Wipf

Cancer Res (2004) 64 (7_Supplement): 1098.

Published: 01 April 2004

View article titled, Pharmacokinetic and pharmacodynamic studies of a novel antitumor wortmannin analogue inhibitor of phosphatidylinositol-3-kinase

Journal Articles

Antitumor activity and pharmacodynamics of PX-478, an inhibitor of hypoxia inducible factor-1Α.

Sarah J. Welsh, Ryan R. Williams, Gillian D. Paine-Murrieta, D. Lynn Kirkpatrick, Garth Powis

Cancer Res (2004) 64 (7_Supplement): 468.

Published: 01 April 2004

View article titled, Antitumor activity and pharmacodynamics of PX-478, an inhibitor of hypoxia inducible factor-1Α.

Journal Articles

The stability of PX-478 in human blood and plasma.

D. Lynn Kirkpatrick, Jeffrey W. Millard, Angela L. Davis, Garth Powis

Cancer Res (2004) 64 (7_Supplement): 486.

Published: 01 April 2004

View article titled, The stability of PX-478 in human blood and plasma.

Journal Articles

Modification of Antitumor Disulfide Cytotoxicity by Glutathione Depletion in Murine Cells

D. Lynn Kirkpatrick

Cancer Res (1987) 47 (16): 4391–4395.

Published: 01 August 1987

View article titled, Modification of Antitumor Disulfide Cytotoxicity by Glutathione Depletion in Murine Cells

NARROW

Abstract A2-29: A PDK1 inhibitors that has antitumor activity in a vemurafenib resistant BRAF(V600E)::NRAS(G12V) melanoma PDX

Abstract 2583: Refinement of inhibitors of the KRAS-signaling naocluster protein, CNKSR1, that block oncogenic KRAS signaling and growth

Abstract 2671: Targeting the KRAS signaling naocluster protein CNKSR1 provides antitumor activity against mutant KRAS xenografts

Abstract 5621: Single-walled carbon nanotubes for delivery of siRNA: Antitumor efficacy comparing formulated complexes in EGFR overexpressing A431 xenografts.

Abstract 4481: Topical application of the dual PDPK1/AKT inhibitor PHT-427 inhibits signaling and growth of human breast cancer cutaneous metastases in mice

Abstract 1975: PHuDock®, a computational discovery and development platform for novel PH domain-binding agents, identifies a novel antitumor AKT/PDPK1 inhibitor, PHT- 427

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

Cellular and in vivo activity of a new PI3K inhibitor-PX866 for treatment of human glioblastoma.

Molecular pharmacology and antitumor activity of palmarumycin based inhibitors of thioredoxin reductase

Clinical surrogate endpoint for the evaluation of HIF-1α inhibition by PX-478.

Pharmacodynamic proteomic studies of the thioredoxin-1 inhibitor PX-12 in mice and patients.

Pharmacokinetic and pharmacodynamic studies of a novel antitumor wortmannin analogue inhibitor of phosphatidylinositol-3-kinase

Antitumor activity and pharmacodynamics of PX-478, an inhibitor of hypoxia inducible factor-1Α.

The stability of PX-478 in human blood and plasma.

Modification of Antitumor Disulfide Cytotoxicity by Glutathione Depletion in Murine Cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only